Evidence map›Paper›PMID 40377023›Full record

ArticleAging cell2025

Nuclear Import Defects Drive Cell Cycle Dysregulation in Neurodegeneration.

Jonathan Plessis-Belair, Taylor Russo, Markus Riessland, Roger B Sher

Abstract read
In one paragraph

Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Jonathan Plessis-BelairDepartment of Neurobiology and Behavior, Stony Brook University, Stony Brook, New York, USA.
Taylor RussoDepartment of Neurobiology and Behavior, Stony Brook University, Stony Brook, New York, USA.
Markus RiesslandDepartment of Neurobiology and Behavior, Stony Brook University, Stony Brook, New York, USA.ORCID 0000-0003-2592-5045
Roger B SherDepartment of Neurobiology and Behavior, Stony Brook University, Stony Brook, New York, USA.ORCID 0000-0003-3327-537X

Funding

Effects of TDP-43 Proteinopathy on Retrotransposon Activation and Cell-Type Specific Vulnerability in a Mammalian Model of Alzheimer's and Related DementiasR01AG079898 · NIA · STATE UNIVERSITY NEW YORK STONY BROOK · PI ROGER B SHER · 2023 to 2026
$2.3M
NIA NIH HHS R01 AG079898NIH HHS R01AG079898Stony Brook UniversityWaterWheel Foundation
6 · The paper itself

Abstract

Neurodegenerative diseases (NDDs) and other age-related disorders have been classically defined by a set of key pathological hallmarks. Two of these hallmarks, cell cycle dysregulation (CCD) and nucleocytoplasmic transport (NCT) defects, have long been debated as being either causal or consequential in the pathology of accelerated aging. Specifically, aberrant cell cycle activation in post-mitotic neurons has been shown to trigger neuronal cell death pathways and cellular senescence. Additionally, NCT has been observed to be progressively dysregulated during aging and in neurodegeneration, where the increased subcellular redistribution of nuclear proteins, such as TAR DNA-Binding Protein-43 (TDP-43), to the cytoplasm is a primary driver of disease. However, the functional significance of NCT defects as either a causal mechanism or consequence of pathology, and how the redistribution of cell cycle machinery contributes to neurodegeneration, remains unclear. Here, we describe that pharmacological inhibition of importin-β nuclear import is capable of perturbing cell cycle machinery both in mitotic neuronal cell lines and post-mitotic primary neurons in vitro. Our Nemf

Indexed as

Cell CycleCell NucleusNeurodegenerative DiseasesActive Transport, Cell NucleusAnimalsbeta KaryopherinsDisease Models, AnimalHumansMiceNeuronsbeta Karyopherinscell cycleneurodegenerationnuclear import

Identifiers

PMID40377023
PMCPMC12341789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.